Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

280.07 +0.06 (+0.02%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
47 48 Next >
The AI Race Gets Litigious
We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029
Explore President Biden's plan to expand Medicare drug negotiations, targeting at least 50 drugs annually. Uncover the impact on pharmaceutical profits and the broader health-care policy proposals,... 
Via Benzinga
(AMGN) - Analyzing Amgen's Short Interest
Via Benzinga
Is It Time to Buy February's 3 Worst-Performing Dow Jones Stocks?
It's only a bargain price if it's actually worth owning. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Amgen Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
This Is What Whales Are Betting On Amgen
Via Benzinga
Behind the Scenes of Amgen's Latest Options Trends
Via Benzinga
It’s Time! 3 Dodgy Pharma Stocks to Sell in February
Explore pharma stocks to sell in February: Eli Lilly, Amgen, BioNTech face overvaluation, volatility, urging investor action. 
Via InvestorPlace
After Soaring 222% in 1 Day, Is Janux Therapeutics Stock a Buy?
The biotech tantalized investors with a very promising data update. 
Via The Motley Fool
Eli Lilly Stock And The Road To 1,000: Weight-Loss Drugs Could Generate $81 Billion
Wall Street isn't properly taking into account Lilly's next-generation drugs, an analyst says. 
Via Investor's Business Daily
Apple Sinks After Wall Street Titan Pulls Magnificent 7 Stock From Conviction List
Goldman Sachs is removing Apple from its Conviction List of buy-rated stocks. Looking at the potential reasons why and who replaced the tech giant. 
Via Benzinga
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Why the dividend investor may take a look at NASDAQ:AMGN.
Exploring AMGEN INC (NASDAQ:AMGN)'s dividend characteristics. 
Via Chartmill
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years
It will take a lot, but this goal isn't out of reach for these stocks. 
Via The Motley Fool
Better Dividend Growth Stock: AbbVie or Amgen?
A strong case can be made for owning both of these dividend growth stocks. But one of them is the better buy. 
Via The Motley Fool
Amazon Stock: Why it's Finally Included in the Dow Index
Amazon replaced Walgreens in the Dow. While a positive move for Amazon, any impact on the stock's price may be limited due to low index weighting. 
Via MarketBeat
Topics Economy Stocks
Exposures Economy US Equities
Amgen's Upcoming Catalysts In 2024 Set To Unlock Multi-Billion Dollar Markets, Says Goldman Sachs
Amgen's growth outlook in 2024, with updates on key programs and upcoming catalysts. Goldman Sachs sees significant opportunities despite exclusivity losses. Dive into potential market moves and... 
Via Benzinga
3 Biotech Stocks to Buy and Hold for the Next 10 Years
There's a lot to like about these three drugmakers right now, and that shouldn't stop anytime soon. 
Via The Motley Fool
Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.
Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy. 
Via Investor's Business Daily
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year. 
Via InvestorPlace
If You Invested $20,000 in Amgen in 2014, This Is How Much You Would Have Today
Has Amgen been a market-beating stock? 
Via The Motley Fool
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness
Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts. 
Via InvestorPlace
7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution
Obesity drug sales boomed in 2023 and will continue in 2024. That could make these weight loss stocks even more attractive. 
Via InvestorPlace
2 Dow Jones Dividend Stocks With Above-Average Yields to Buy Now and Hold for at Least a Decade
Investors interested in a steadily rising stream of passive income will find what they're looking for with these dividend payers. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Amgen Takes Aim at Novo Nordisk and Eli Lilly, but Is the Stock a Buy?
It faces both clinical and competitive barriers, but they might not matter. 
Via The Motley Fool
Drivers And Stock Pickers
As opposed to drivers who overestimate themselves, we seek to be above-average stock pickers by doing the things that most professional investors struggle with, like being courageous and patient. 
Via Talk Markets
Stock Market Hits Highs As AI Plays Arm, Palantir Skyrocket: Weekly Review
The S&P 500 hit 5,000. Arm, Palantir and Cloudflare rose sharply. 
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Are these frigid Dow stocks in for a longer winter?
These three Dow laggards have suffered double-digit percentage declines this winter, contributing to the Dow’s underperformance versus other major averages. 
Via MarketBeat
Topics Economy Stocks
Exposures Economy US Equities
2 Unstoppable Stocks to Buy and Hold for 2024 and Beyond
These great businesses are persisting and thriving through challenging economic times. 
Via The Motley Fool
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
47 48 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.